Published in Neurol Sci on November 14, 2015
Fruitflow(®): the first European Food Safety Authority-approved natural cardio-protective functional ingredient. Eur J Nutr (2016) 0.75
Natural and Synthetic Neurotoxins in Our Environment: From Alzheimer's Disease (AD) to Autism Spectrum Disorder (ASD). J Alzheimers Dis Parkinsonism (2016) 0.75
Advances in clinical neurology through the journal "Neurological Sciences" (2015-2016). Neurol Sci (2017) 0.75
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet (2010) 11.00
Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol (1998) 7.22
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol (2003) 5.51
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet (1997) 5.27
Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA (2010) 5.10
Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet (2012) 4.85
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88
Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol (2014) 3.73
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol (2012) 3.37
A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J (2007) 3.32
Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA (2007) 3.28
Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol (2001) 2.99
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ (2008) 2.98
The role of aspirin in cancer prevention. Nat Rev Clin Oncol (2012) 2.94
Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain (2007) 2.93
The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol (2008) 2.79
Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study. Arch Neurol (2009) 2.67
Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ (2004) 2.46
Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol (2003) 2.26
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol (2009) 2.11
Mechanisms of variability in antiplatelet agents response. Thromb Res (2012) 2.00
Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 1.74
Aspirin: a historical and contemporary therapeutic overview. Circulation (2011) 1.74
Cerebral microbleeds and cognition in patients with symptomatic small vessel disease. Stroke (2013) 1.72
Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based, case-control study. J Neurol Neurosurg Psychiatry (2010) 1.65
Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol (2011) 1.51
Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol (2010) 1.51
Over-expression of the LTC4 synthase gene in mice reproduces human aspirin-induced asthma. Clin Exp Allergy (2011) 1.45
Association of cyclooxygenase-2 genetic variant with cardiovascular disease. Eur Heart J (2014) 1.39
Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation (2011) 1.33
Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther (2005) 1.32
Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. AJNR Am J Neuroradiol (2012) 1.26
Physiology. COX-2 inhibitors and cardiovascular risk. Science (2012) 1.19
Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages. Neurology (2003) 1.17
Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol (2012) 1.16
Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications. Biochimie (2010) 1.13
Platelet function tests: a comparative review. Vasc Health Risk Manag (2015) 1.11
Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol (2012) 1.08
The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum (2000) 1.07
The metabolism of aspirin in man: a population study. Xenobiotica (1986) 1.07
New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals. Thromb Res (2013) 1.07
Risk of hemorrhagic stroke with aspirin use: an update. Stroke (2005) 1.06
Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost (2005) 1.04
Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case-control study in a new general practice database. Eur J Clin Pharmacol (2012) 1.03
Renal effects of low dose aspirin in elderly patients. Isr Med Assoc J (2006) 0.98
An evidence based flowchart to guide the management of acute salicylate (aspirin) overdose. Emerg Med J (2002) 0.97
Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J Clin Endocrinol Metab (2010) 0.93
Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol (2006) 0.93
Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer. Best Pract Res Clin Gastroenterol (2011) 0.91
Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes. Front Pharmacol (2010) 0.91
Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. J Gastroenterol (2013) 0.89
The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis. Br J Clin Pharmacol (2014) 0.88
Aspirin-induced peptic ulcer and genetic polymorphisms. J Gastroenterol Hepatol (2010) 0.86
Genetic determinants of response to aspirin: appraisal of 4 candidate genes. Thromb Res (2011) 0.84
Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures. Thromb Haemost (2012) 0.84
Association of COX-2 rs20417 with aspirin resistance. J Thromb Thrombolysis (2013) 0.83
Currently available methods for platelet function analysis: advantages and disadvantages. Cardiovasc Revasc Med (2010) 0.80
Brain microbleeds. Pract Neurol (2010) 0.79
Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease. Int J Lab Hematol (2015) 0.78
Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly Chinese patients with cardiovascular disease. Gerontology (2012) 0.78
The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin. Thromb Res (2010) 0.78
The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease. Semin Nephrol (1995) 0.77
Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients? Int J Clin Pharm (2015) 0.77
Aspirin and age-related macular degeneration: positives versus negatives. Expert Opin Drug Saf (2014) 0.76
Aspirin and aspirin resistance in coronary artery disease. Curr Opin Pharmacol (2013) 0.76
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. J Thromb Thrombolysis (2014) 0.76
The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. PLoS One (2013) 0.75
The effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primary haemostasis under influence of aspirin - a randomized controlled trial. BMC Anesthesiol (2015) 0.75
Clopidogrel Resistance after Minor Ischemic Stroke or Transient Ischemic Attack is Associated with Radiological Cerebral Small-Vessel Disease. J Stroke Cerebrovasc Dis (2015) 0.75
Minimal withdrawal of dual antiplatelet agents under the guidance of a point-of-care platelet activity assay early after drug-eluting stent implantation for surgical removal of renal cell carcinoma. Int J Cardiol (2009) 0.75
Prediction of antiplatelet effects of aspirin in vivo based on in vitro results. Clin Appl Thromb Hemost (2013) 0.75